CTOs on the Move


 
Dyadic uses its proprietary C1 platform technology to discover and develop novel genes and other biological products from eukaryotic organisms found in the full spectrum of the earth’s biodiversity. Once useful genes are isolated, Dyadic uses its integrated platform to manufacture specific proteins, doing so more rapidly and efficiently — and with a much higher rate of success than existing gene discovery systems. Dyadic leverages its proprietary technology platform to discover novel genes and biological products for use by its strategic partners, and to further its own R&D efforts. Dyadic seeks strategic alliances with major leaders in the agricultural, bioenergy, industrial enzyme, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.dyadic.com
  • 140 Intracoastal Pointe Dr Ste 404
    Jupiter, FL USA 33477
  • Phone: 561.743.8333

Executives

Name Title Contact Details

Similar Companies

Picometrics

Picometrics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ConjuGon Inc

ConjuGon Inc is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stembanc

Stembanc is a Chardon, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Islet Sciences

Islet Sciences is a clinical stage biotechnology company engaged in the research, development, and commercialization of new medicines and technologies for the treatment and diagnosis of metabolic disease and related indications where there is significant measurable unmet medical need. The rising incidence of obesity is associated with many obesity-related health complications, including cardiovascular disease, diabetes, hyperlipidemia, hypertension, nonalcoholic fatty liver disease/steatohepatitis (NAFLD/NASH). This constellation is also recognized as the metabolic syndrome and is characterized by underlying insulin resistance. These various diseases have interrelated risk factors and markers, such that often treatment of one disease may allow new therapies and opportunities for treatment in one of these related indications. Our focused effort to develop new therapies and related diagnostics for metabolic related diseases establishes us as a recognized leader in a large and growing market.